The biotech company view

Article Abstract:

The present state of antibiotic drug development is a process in transition as many large pharma companies have withdrawn from major discovery efforts to identify new classes of drugs to address the growing problem of antimicrobial drug resistance. Smaller biotech companies, however, are able to attract the capital investment to continue the discovery of new antimicrobial drugs.

Industry overview

---

Becoming an American company: A holistic approach to decision making

Article Abstract:

The U.S. market is representing the best way to financial success for most of the biotech and pharmaceutical companies, thereby making it a necessity for most of them to set up a U.S. location. The companies will have to consider the cost consequences and value drivers as part of a global execution strategy before setting up a U.S. base.

General services, Subsidiary corporations, Subsidiaries, New business enterprises, Startups, Business success, Logistics

---

Sidney Wolfe

Article Abstract:

The criticism and bold expressions of Sidney Wolfe of the U.S. Food and Drug Administration (FDA) about the drugs, companies and the FDA, has led to him being regarded as an anti-pharma activist and a disgrace for the FDA, but the US public are increasingly echoing his views and losing trust in the drug industry.

Beliefs, opinions and attitudes, United States. Food and Drug Administration, Wolfe, Sidney

Similar abstracts:

• Abstracts: Antiinfective biotechs face partnering gap. A taste of the future
• Abstracts: Chasing biotech, state by state-winners and losers. Shareholders flex their muscles
• Abstracts: Research issues in building brand equity and global brands in the pc market. Internationalization of services brands: the role of leadership during the internal brand building process
• Abstracts: Finally the party can start. Journal of Accounting and Public Policy: 25th anniversary. The impact of the Sarbanes-Oxley Act on the corporate disclosures of information security activities
• Abstracts: Think tanks: giving PR a bad name. N.Y., Chicago, S.F. firms show robust growth

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.